Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €248.43 EUR
Change Today -2.96 / -1.18%
Volume 7.3K
RHO On Other Exchanges
SIX Swiss Ex
SIX Swiss Ex
As of 1:43 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-br (RHO) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/1/15 - €270.00
52 Week Low
10/13/14 - €201.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ROCHE HOLDING AG-BR (RHO)

roche holding ag-br (RHO) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Europe, North America, and Asia. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, drug metabolism disorder, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, human papillomavirus, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and west nile virus diseases. The company also provides diagnostic solutions for blood gas analysis; blood screening; cancer screening; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring, routing, and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogenous immune assays; immunology; infectious diseases; intensive care testing; microarray; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; pharmacogenomics; physical fitness and platelet function testing; PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. In addition, it offers products for researchers, such as amplification, cell analysis, gene expression, gene knockdown, genome sequencing, microarrays, nucleic acid purification, protein analysis, PCR systems, and transfection products. The company has collaboration agreements with AmorChem, AbbVie, Xenon Pharmaceuticals, Stratos Genomics, The Garvan Institute, Cornell University, and University of Washington. The company was founded in 1896 and is headquartered in Basel, Switzerland.

88,509 Employees
Last Reported Date: 01/28/15
Founded in 1896

roche holding ag-br (RHO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.3M
Chief Financial Officer and IT Officer
Total Annual Compensation: SFr.4.1M
Chief Operating Officer of Pharmaceuticals di...
Total Annual Compensation: SFr.5.0M
Chief Operating Officer of Diagnostics Divisi...
Total Annual Compensation: SFr.2.5M
General Counsel and Corporate Secretary
Total Annual Compensation: SFr.2.8M
Compensation as of Fiscal Year 2014.

roche holding ag-br (RHO) Key Developments

Roche And Johnson & Johnson Eyes Stake In GlaxoSmith

Swiss-based Roche Holding AG (SWX:ROG) and U.S.-based Johnson & Johnson are eying the U.K. company for approximately $143 billion. Moreover, there is also a rumor that Pfizer Limited (BSE:500680) was considering acquiring GlaxoSmithKline plc (LSE:GSK) a year after it failed to acquire AstraZeneca PLC. As per the poll conducted by BioSpace, AstraZeneca PLC could also be in the race to acquire struggling GlaxoSmithKline.

Roche, Pfizer, Johnson & Johnson And AstraZeneca In Race To Acquirer GlaxoSmithKline

Roche Holding AG (SWX:ROG) and Johnson & Johnson (NYSE:JNJ) are looking to buy GlaxoSmithKline plc (LSE:GSK) ('Glaxo') for approximately $143 billion. There is rumor that Pfizer Limited (BSE:500680) may also be considering acquiring Glaxo. As per the poll conducted by BioSpace, AstraZeneca plc (LSE:AZN) could also be in the race to acquire struggling GlaxoSmithKline.

Roche to Provide HIVDiagnostic Solutions to Global Fund

Roche announced that it has been selected to provide HIV-1 viral load and early infant diagnostic technologies for the Global Fund. This marks a further step in the collaboration between Roche and the Global Fund, an organization that has pioneered providing effective and economic solutions for healthcare to achieve the best results for patients. The HIV-1 tests1 eligible for the Global Fund collaboration utilize a unique dual-target design to simultaneously amplify and detect two separate regions of the HIV-1 genome, which are not subject to selective drug pressure. This innovative fully-automated solution will provide reliable results for laboratories and physicians to more confidently and efficiently treat HIV-1 patients undergoing therapy. For early infant diagnostics, the dual-target HIV-1 qualitative test, v2.02 works with both plasma and dried blood spot (DBS) collection cards, eliminates the need for refrigeration, drastically reduces the volume of blood required and makes sample collection and transportation easy, even from the smallest infant in the most rural area.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHO:GR €248.43 EUR -2.96

RHO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $115.46 USD -4.04
Merck & Co Inc $57.29 USD -1.20
Novartis AG SFr.92.30 CHF -1.00
Pfizer Inc $33.59 USD -0.33
Sanofi €89.53 EUR -3.43
View Industry Companies

Industry Analysis


Industry Average

Valuation RHO Industry Range
Price/Earnings 26.5x
Price/Sales 4.9x
Price/Book 12.4x
Price/Cash Flow 21.5x
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-BR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at